Pfizer Receives Positive CHMP Opinion for LORVIQUA (lorlatinib) for Certain Adult Patients with Previously-Treated ALK-Positive Advanced Non-Small Cell Lung Cancer
NEW YORK--(BUSINESS WIRE)--Mar 1, 2019--Pfizer today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a p…
